COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention updated its guidance on how COVID-19 spreads to acknowledge published reports showing 鈥渓imited, uncommon鈥 circumstances where people with COVID-19 infected others who were more than 6 feet away.
The Centers for Disease Control and Prevention released guidance to help health care and public health providers prevent HIV outbreaks among people who inject drugs, including considerations for delivering services during the COVID-19 pandemic.
CMS releases guidance on COVID-19 data reporting as a condition of hospitals鈥 Medicare participation
The Centers for Medicare & Medicaid Services released guidance on how it will implement its August interim final rule that makes collecting and reporting COVID-19 data a condition of participation for hospitals that participate in Medicare.
The Food and Drug Administration on Oct. 7 will host the first in a series of virtual Town Halls to answer technical questions about test development and validation for SARS-CoV-2, the virus that causes COVID-19.
The Food and Drug Administration posted updated comparative performance data for molecular tests to diagnose the COVID-19 virus.
Weekly COVID-19 cases among college-aged youth increased 55% nationally between Aug. 2 and Sept. 5, according to a report released by the Centers for Disease Control and Prevention.
States and COVID-19 testing laboratories have reported more than 277,000 COVID-19 cases in school-aged children since March, with about twice as many cases in children aged 12-17 than younger children, the Centers for Disease Control and Prevention reported.
The Food and Drug Administration authorized for emergency use the first serology test to help identify individuals with antibodies to SARS-CoV-2 at the point of care.
The Food and Drug Administration reissued its emergency use authorization for the Abbott ID NOW COVID-19 test to indicate that the product is intended for specimens collected 鈥渇rom individuals who are suspected of COVID-19 by their health care provider within the first seven days of the onset of鈥
The Food and Drug Administration approved a new drug application for propofol injectable emulsion, an intravenous general anesthetic and sedation drug in short supply.